2019
Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center
Browning S, Parker T, Bar N, Seropian S, Lee A, Anderson T, Neparidze N. Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center. Blood 2019, 134: 5569. DOI: 10.1182/blood-2019-130134.Peer-Reviewed Original ResearchSmilow Cancer HospitalMultiple myelomaRefractory MMInfusion reactionsSpeakers bureauCancer HospitalReal-word experienceReal-world practice patternsAnti-plasma cell therapyTransplant-eligible patientsYale Cancer CenterInfusion-related reactionsAdverse event profileLeukotriene receptor antagonistsProgression-free survivalRefractory multiple myelomaPatient-reported qualityManagement of patientsOverall response rateJanssen Scientific AffairsClonal plasma cellsExcellent safety profileMulti-center studyDrug combination regimensInfusion reaction rates
2012
Cutaneous Toxicity Associated with Pralatrexate in Cutaneous and Peripheral T-Cell Lymphoma
Parker T, Barbarotta L, Girardi M, Foss F. Cutaneous Toxicity Associated with Pralatrexate in Cutaneous and Peripheral T-Cell Lymphoma. Blood 2012, 120: 3660. DOI: 10.1182/blood.v120.21.3660.3660.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaCutaneous T-cell lymphomaT-cell lymphomaRefractory cutaneous T-cell lymphomaRefractory peripheral T-cell lymphomaCutaneous toxicityMajority of patientsAdverse eventsMedian ageSkin flareMedian numberLow doseDiagnosis of PTCLCommon adverse eventsSpeakers bureauOff-label useIntravenous antibioticsCTCL patientsFirst doseToxic erythemaDose escalationCTCL lesionsMoist desquamationRetrospective reviewSkin breakdown